Authors
Latest:
Dr Barry on the Rationale for Using Partial Breast Irradiation in Breast Cancer ManagementParul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.
Latest:
Oncology Experts Preview Top Abstracts From the 2024 ESMO CongressExperts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.
Latest:
Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS AnalysisExpert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.
Latest:
Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 PandemicJames H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.
Latest:
Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple MyelomaFrancesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.
Latest:
Dr Foster on Daratumumab/Lenalidomide Maintenance in Newly Diagnosed Multiple MyelomaLaahn Ho Foster, MD, discusses the potential role of daratumumab plus lenalidomide maintenance in multiple myeloma after ASCT.
Latest:
Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast CancerJeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.
Latest:
Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer LandscapeA panel of experts offer future perspectives in HR+ breast cancer.
Latest:
Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual MeetingDrs Thomas and Lukas discusses highlights in brain cancer research from the 2024 ASCO Annual Meeting.
Latest:
Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian CancerBurak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.
Latest:
Surgical Intervention Provides the Foundation for Exploring Immunotherapy in GlioblastomaBecause the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.
Latest:
How Biomarker Testing Could Continue to Evolve in NSCLCJessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Latest:
Dr Wang on the Role of Active Surveillance in Patients With Renal MassesKatherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
Latest:
Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple MyelomaVarious immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.
Latest:
Precision Cancer Care: Preserving Normal Tissue With Proton TherapyRadiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.
Latest:
The Medical AI RevolutionWe consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.
Latest:
Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain MetastasesRupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.
Latest:
Dr Kaczmar on the Future Utility of Cemiplimab With Fianlimab in Advanced MelanomaJohn Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.
Latest:
Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer ManagementKian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.
Latest:
Dr Katz on a Cystoscopic Cryocatheter in Bladder CancerAaron E. Katz, MD, discusses the rationale for and findings from a preclinical study evaluating the efficacy of a novel cystoscopic cryocatheter for in situ bladder cancer destruction.
Latest:
Barbara Ann Karmanos Cancer Institute and Wayne State University Name Boris C. Pasche, MD, PhD, FACP, President and Chief Executive OfficerThe Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.
Latest:
Practical Advice for Management of Chronic GVHDThe panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.
Latest:
Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trialRyan Hickey, MD, presents data from the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium on results of the phase 2 DOSISPHERE-01 trial of personalized vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma.
Latest:
Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung CancerArya Amini, MD, discusses cardiac toxicities associated with lung cancer.
Latest:
Investigators Explore Immunotherapy for NETs as Incidence GrowsTo date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.
Latest:
Dr Roland on a Study of Neoadjuvant Immune-Checkpoint Blockade Across Sarcoma SubtypesChristina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.
Latest:
Future Outlooks in the Treatment of R/R DLBCLShared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Latest:
Dr Mateos on Belantamab Mafodotin Plus Bortezomib/Dexamethasone in R/R MyelomaMaría-Victoria Mateos, MD, PhD, discusses findings for belantamab mafodotin plus bortezomib and dexamethasone.
Latest:
Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AIAWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.
